FDA Warns of Risk for PE, Death With Higher Dose Xeljanz - Medscape

FDA Warns of Risk for PE, Death With Higher Dose Xeljanz  Medscape

The FDA is warning of an increased risk for pulmonary embolism and death in patients with rheumatoid arthritis who received tofacitinib (Xeljanz, Xeljanz XR) 10 ...



Comments

Popular posts from this blog

Fibromyalgia — Latest Stories — Pain News Network

Chronic Lyme arthritis: A mystery solved?

Epstein-Barr virus and autoimmune diseases